Navigation Links
Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
Date:5/21/2012

e treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for Zerenex (ferric citrate) may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability, and our Japanese partner's ability, to successfully and cost-effectively complete clinical trials for Zerenex (ferric citrate); the risk that the data (both safety and efficacy) from the ongoing Phase 3 trials for Zerenex (ferric citrate) will not coincide with the data analyses from previous clinical trials reported by us and our Japanese partner; our ability to meet anticipated development timelines for Zerenex due to clinical trial results, manufacturing capabilities or other factors; our ability to replicate in our ongoing long-term Phase 3 clinical study the effects on iron storage parameters, intravenous (IV) iron and erythropoiesis-stimulating agent (ESA) use observed in previous clinical trials; the ability for Zerenex to generate cost savings for dialysis centers and payers; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this pres
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 Pharmacyclics, Inc. ... that The New England Journal of Medicine ... 1b/2 study evaluating the investigational oral Bruton,s tyrosine kinase ... leukemia (CLL) or small lymphocytic lymphoma (SLL). Ibrutinib was ... relapsed/refractory CLL or SLL, even in patients who were ...
(Date:6/19/2013)... BELLEVUE, Wash. , June 19, 2013 ... Provisioning version 4.0, a solution designed to ... to applications and data while supporting their ... release of Provisioning represents a milestone in ... governance and analytics capabilities for health systems. ...
(Date:6/19/2013)... June 19, 2013 ... added DrugPatentWatch to its extensive list ...      (Logo: http://photos.prnewswire.com/prnh/20130128/590935) , ... on pharmaceutical, drug patents and their ... critical business functions of patent agents ...
Breaking Medicine Technology:Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 2Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 3Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 4Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 5Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 6Caradigm Provisioning Helps Healthcare Organizations Improve Clinical Efficiency, Manage Risk 2Caradigm Provisioning Helps Healthcare Organizations Improve Clinical Efficiency, Manage Risk 3Drug Patent Watch 2Drug Patent Watch 3
(Date:6/20/2013)... Bournemouth, Dorset (PRWEB) June 20, 2013 ... disease) and more serious medical conditions because they do ... of Eludril mouthwash and Elgydium toothpaste. , Seven million ... leaving it 48 hours between brushes, latest data from ... per cent of people polled by the BDHF also ...
(Date:6/20/2013)... Michigan-based natural health and wellness coach ... Hamilton which revealed that performing random acts of kindness ... release of the feel-good hormone Oxytocin in the brain ... the ‘cardio protective’ hormone because it temporarily lowers blood ... , “Being kind is something we can all do, ...
(Date:6/20/2013)... (PRWEB) June 20, 2013 Startups who ... energize their sales or test new markets, and international ... now have a new sales outsourcing company ... sales revenue. , Strategy Sales Partners is ... Founded by business owners for business owners, Strategy Sales ...
(Date:6/20/2013)... Creighton University was named to the ... the highest federal recognition a college or university can ... and civic engagement as well as meaningful community outcomes. ... and Community Service, is given to 690 schools nationwide ... Creighton is based on spiritual growth through service to ...
(Date:6/19/2013)... With the winter season having begun ... winter season Santiago day trips schedule. Offering ... and around Santiago this season, expert mountain guides from ... for backcountry skiing, challenging rock climbing adventures, and trekking ... dreamed of skiing in Chile , Chile Montaña ...
Breaking Medicine News(10 mins):Health News:Millions Are Risking Gum Disease, Warn Eludril And Elgydium 2Health News:Millions Are Risking Gum Disease, Warn Eludril And Elgydium 3Health News:Kindness Can Be Good for The Heart Says BioGirl Health Show 2Health News:Kindness Can Be Good for The Heart Says BioGirl Health Show 3Health News:Strategy Sales Partners Launches to Provide Sales Outsourcing Assistance to Businesses 2Health News:Strategy Sales Partners Launches to Provide Sales Outsourcing Assistance to Businesses 3Health News:Creighton Again Named to President’s Honor Roll - University Picks Up Sixth Recognition Award for Service 2Health News:Creighton Again Named to President’s Honor Roll - University Picks Up Sixth Recognition Award for Service 3Health News:Chile Montaña Announces Winter Season Santiago Day Trips 2Health News:Chile Montaña Announces Winter Season Santiago Day Trips 3
... Canadian Study finds that adolescence boys are at higher risk ... Researchers have found that the seeds of hypertension and its ... management, lack of exercise, obesity are some of the factors ... in heart damages. ,In the study which began ...
... following an E. coli outbreak. In the last fortnight, at ... diarrhea. They were diagnosed with E coli infection. ... Inc in New Jersey have been incriminated as the most ... that they had eaten from one of the three Taco ...
... its annual meeting at Nashville on 4 th December. ... for// the need to move in a new direction ... ,The panel consisted of representatives from academics, ... the delay in the development of novel treatments for ...
... Academy of Pediatrics blames inappropriate advertising to be the ... government to impose bans and restrictions on// advertising to ... of New Mexico's Doctor and the lead author of ... ads per year on television alone and increasingly are ...
... health awareness in rural areas - puppets.// ... Raje last week informs the rural poor on the ... shows and cultural programmes. ,The month-long 'Swasthaya ... health-related information with the help of local artistes in ...
... have fast food outlets in their site, thus giving an ... reality it is not. According to a report in the// ... 200 hospitals had fast food outlets. ,Dr. Hannah ... two different messages by being in the health care profession ...
Cached Medicine News:Health News:Teen Boys At Greater Risk To High Blood Pressure Than Girls 2Health News:Research In A New Direction To Develop Innovative Psychotropic Drugs 2Health News:Research In A New Direction To Develop Innovative Psychotropic Drugs 3
... is the aqueous ... It is a fast-acting, ... gram-positive and gram-negative bacteria ... as well as most ...
... the one-step prep solution, allows the user ... applies and dries in less than 2-minutes. ... commonly used in surgical scrubbing and healthcare ... added to help provide a tacky surface ...
... designed for individual application and are ideal ... nursing homes, home healthcare settings, blood banks, ... departments. This unit dose pouch contains hydrogen ... and cleansing agent. Hydrogen Peroxide's chief value ...
... This multi-purpose topical solution ... Povidone Iodine Prep Spray is ... the possibility of cross contamination. ... an alternate method to the ...
Medicine Products: